clinical trial · NCT07695298
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
Cincinnati Eye Institute, Southwest Ohio·phase4·recruiting·n = 25
Presumed Ocular HistoplasmosisFaricimab Injection [Vabysmo]
brief summary
This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)
started
Jul 1, 2026
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Jul 10, 2026
official title
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol